Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

NCT03654729 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

291

Enrollment

INDUSTRY

Sponsor class

Stopped On 23 January 2020, the Sponsor announced that the United States (US) Food and Drug Administration (FDA) had issued a clinical hold in the US of the POLAR program.

Conditions

Colorectal Cancer
Chemotherapy-induced Peripheral Neuropathy

Interventions

DRUG: Calmangafodipir (2 µmol/kg)
DRUG: Calmangafodipir (5 µmol/kg)
DRUG: Placebo

Sponsor

Egetis Therapeutics

Collaborators

[object Object]